X0609 4 2026-06-23 0 0001636282 Spyre Therapeutics, Inc. SYRE 0001802528 Fairmount Funds Management LLC false 200 BARR HARBOR DRIVE SUITE 400 WEST CONSHOHOCKEN PA 19428 1 0 0 0 0001769651 Fairmount Healthcare Fund II L.P. false 200 BARR HARBOR DRIVE SUITE 400 WEST CONSHOHOCKEN PA 19428 1 0 0 0 0001830177 Kiselak Tomas false 200 BARR HARBOR DRIVE SUITE 400 WEST CONSHOHOCKEN PA 19428 1 0 0 0 0001663607 Harwin Peter Evan false 200 BARR HARBOR DRIVE SUITE 400 WEST CONSHOHOCKEN PA 19428 1 0 0 0 0 Common Stock 2026-06-23 4 C 0 666680 A 4684781 I By Fairmount Healthcare Fund II L.P. Common Stock 2026-06-23 4 S 0 4684781 85.31 D 0 I By Fairmount Healthcare Fund II L.P. Common Stock 406038 I By Tomas Kiselak Common Stock 406038 I By Peter Harwin Series B Preferred Stock 2026-06-23 4 C 0 16667 0.00 D Common Stock 666680 0 I Fairmount Healthcare Fund II LP Series A Preferred Stock Common Stock 13841800 346045 I Fairmount Healthcare Fund II LP Each share of Series B Preferred Stock is convertible at the option of the holder into 40 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On June 23, 2026, the Reporting Persons converted 16,667 shares of Series B Preferred Stock into 666,680 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designations for the Series B Convertible Preferred Stock. Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Each share of Series A Preferred Stock is convertible at the option of the holder into 40 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Reporting Persons may each be deemed a director by deputization of Issuer by virtue of the fact that Tomas Kiselak serves on the board of directors of Issuer and is also a Managing Member of Fairmount Funds Management LLC. /s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC 2026-06-23 /s/ Tomas Kiselak, Managing Member of Fairmount Healthcare Fund II, L.P. 2026-06-23 /s/ Tomas Kiselak 2026-06-23 s/ Peter Harwin 2026-06-23